Maxcyte Inc

Maxcyte (MXCT)

Company name:Maxcyte Inc
Company Description:MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology
EPIC:MXCTTrading Currency:GBX
Market Sector:AMQ1ISIN:
Market Segment:ASQ1Share Type:DE
WWW Address: STK USD0.01 (DI)
 Price Price Change [%] Bid Offer Open High Low Volume
 299.00 5.0 [1.70] 298.00 300.00 292.00 302.00 292.00 189,320
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 199.39 66.68 0.10 -17.52 - - - 302.00 - 105.00

Maxcyte Key Figures

(at previous day's close)
Market Cap.199.39m
Shares In Issue66.68m
Prev. Close294.00
PE Ratio- 
Dividend Yield-%
EPS - basic-17.52p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-9.95p
Return On Equity (ROE)-94.80%
Operating Margin-59.64%
PEG Factor- 
EPS Growth Rate-35.29%
Dividends PS Growth Rate-%
Net Debt0.88m
Gross Gearing54.64%
Quick Assets14.52m
Net Working Capital10.26m
Intangibles / Fixed Assets32.05%
Turnover PS24.45p
Pre-Tax Profit PS-14.58p
Retained Profit PS-14.58p
Cash PS17.20p
Net Cash PS6.63p
Net Tangible Asset Value PS *12.83p
Net Asset Value PS15.38p
Spread2.00 (0.67%) 

Maxcyte Balance Sheet


Share Price Performance

Sample Period HighLow
1 week302.00241.00
4 weeks302.00205.00
12 weeks302.00165.00
1 year302.00105.00

Share Price Chart (5 years)

Maxcyte Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week241.0058.0024.07241.000.08278.74
4 weeks205.0094.0045.85205.000.28230.33
12 weeks180.00119.0066.11165.000.15215.68
26 weeks150.00149.0099.33122.500.09201.28
1 year122.00177.00145.08105.000.09175.89
3 years242.5056.5023.30105.000.05180.43
5 years72.50226.50312.4172.500.04179.85

Maxcyte Key Management Ratios

Maxcyte Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 7.35 
Tobin's Q Ratio (excl. intangibles)7.67 
Dividend Yield-%
Market-to-Book Ratio19.44 
Price-to-Pre-Tax Profit PS-20.51 
Price-to-Retained Profit PS-20.51 
Price-to-Cash Flow PS-30.04 
Price-to-Sales PS12.23 
Price-to-Net Tangible Asset Value PS23.30 
Price-to-Cash PS17.38 
Net Working Capital PS15.39 
Price Pct to Working Capital PS19.43%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Maxcyte Financial Ratios

(Leverage Ratios)
Debt Ratio34.11%
Debt-to-Equity Ratio0.52 
Debt-to-Equity Ratio (excl. Intgbl)0.62 
Debt-to-Equity Market Value0.03 
Net Gearing3.91%
Net Gearing (excl. Intangibles)4.23%
Gross Gearing54.64%
Gross Gearing (excl. Intangibles)59.08%
Gearing Under 1 Year31.16%
Gearing Under 1 Year (excl. Intgbl)33.69%
(Liquidity Ratios)
Net Working Capital to Total Assets45.39%
Current Ratio2.46 
Quick Ratio (Acid Test)2.06 
Liquidity Ratio1.63 
Cash & Equiv/Current Assets66.27%
(Solvency Ratios)
Enterprise Value193.23m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.06 
Total Debt/Sales0.76 
Total Debt/Pre-Tax Profit-1.27 
Total Debt12.35m
Total Debt/Net Current Assets1.20%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-34.17%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs2 
Beta (60-Mnth)Beta (36-Mnth)

Maxcyte Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-62.47%
Return On Assets (ROA)-35.84%
Net Profit Margin-59.64%
Assets Turnover0.60 
Return On Equity (ROE)-94.80%
Return On Investment (ROI)-50.72%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-59.64%
(Asset Utilisation Multiples)
Shareholders Equity Turnover1.26 
Fixed Assets Turnover2.71 
Current Assets Turnover0.77 
Net Working Capital Turnover 
Inventory Turnover5.48 
(Other Operating Ratios)
Total Assets-to-Sales1.66 
Debt Collection Period91.22Days

Maxcyte Dividends

Sorry No Data Available

Maxcyte Fundamentals

 31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
pre tax profit-3.35-27.27%-9.92-79.13%-8.87-53.21%-12.90-59.64%m
attributable profit-3.85-31.39%-9.92-79.13%-8.87-53.21%-12.90-59.64%m
retained profit-3.85-31.39%-9.92-79.13%-8.87-53.21%-12.90-59.64%m
eps - basic-11.00 -20.00 -17.00 -23.00 
eps - diluted-11.00 -20.00 -17.00 -23.00 
dividends per share- - - - 

Maxcyte Balance Sheet

 31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
 31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
fixed assets fixed assets0.281.75%0.852.70%1.827.49%3.2810.94%m
intangibles intangibles--%--%--%2.257.51%m
fixed investments fixed investments--%--%3.1913.15%1.505.00%m
current assets - other current assets - other0.321.98%0.672.12%0.863.56%0.802.66%m
stocks stocks1.338.30%1.354.29%2.249.24%3.7012.35%m
debtors debtors2.4115.00%3.2010.18%4.9020.21%3.2410.82%m
cash & securities cash & securities11.7372.96%25.3480.71%11.2546.35%15.2150.73%m
creditors - short creditors - short5.6535.17%7.2423.06%6.5727.08%9.3431.16%m
creditors - long creditors - long--%--%--%--%m
creditors - other creditors - other5.3433.21%4.5614.53%5.4122.31%7.0423.48%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves5.0831.63%19.6062.41%12.2850.61%13.6045.36%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Maxcyte Cash Flow Statement

31 Dec 2016 (USD)31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)
Operating CF-2.34-9.68-10.49-8.80m
Pre-Financing CF-2.55-10.29-14.32-8.35m
Retained CF9.3213.61-14.093.96m

Maxcyte Brokers

Broker infomation is not available for this class of stock.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200807 09:43:54